Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate

Ezziddin, Samer; Sabet, Amir; Heinemann, Florian; Yong-Hing, Charlotte J; Ahmadzadehfar, Hojjat; Guhlke, Stefan; Höller, Tobias; Willinek, Winfried; Boy, Christian; Biersack, Hans-Jürgen (2011). Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. Journal of nuclear medicine, 52(8), pp. 1197-203. New York, N.Y.: Society of Nuclear Medicine 10.2967/jnumed.111.090373

Full text not available from this repository. (Request a copy)

Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs), with outstanding overall response rates and survival. However, little is known about the particular efficacy regarding bone metastasis (BM).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Boy, Christian

ISSN:

0161-5505

Publisher:

Society of Nuclear Medicine

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:19

Last Modified:

11 Apr 2019 15:55

Publisher DOI:

10.2967/jnumed.111.090373

PubMed ID:

21764798

Web of Science ID:

000293336000033

URI:

https://boris.unibe.ch/id/eprint/6165 (FactScience: 211067)

Actions (login required)

Edit item Edit item
Provide Feedback